Press conferences may be viewed live at or archived at

Transcription

1 PRESS CONFERENCES HIV RESEARCH FOR PREVENTION (HIVR4P 2018) Media Center: Pottsdam/Baden Baden rooms, Madrid Marriott Auditorium Hotel Embargoes on oral abstract studies lift at the conclusion of the study s presentation in either an HIVR4P press conference or in an official conference session, whichever is earlier. Embargoes on all poster presentations lift on Tuesday, 23 October at CEST or at the conclusion of presentation of the study in an HIVR4P press conference, whichever is earlier. Embargoes apply to traditional and social media. Press conferences may be viewed live at or archived at Monday, 22 October (3:00 4:00 pm) CEST Welcome to HIVR4P 2018 and Conference Overview Jose Alcamí, Conference Co-chair, Instituto de Salud Carlos III, Spain Susan Buchbinder, Conference Co-chair, San Francisco Department of Public Health, U.S. Presentation of the International AIDS Society (IAS) Global HIV Vaccine Strategy Linda-Gail Bekker, Desmond Tutu HIV Foundation, South Africa Vaccine and antibody research Moderator: John Mascola, NIAID, National Institutes of Health, U.S. Oral Abstract Session 2 Immunity in Human Vaccine Trials (Tuesday, 22 October ) OA02.05LB. Vaccine-induced Gene Signature Correlates with Protection against Acquisition in Three Independent Vaccine Efficacy Trials Including RV144 Rasmi Thomas, US Military HIV Research Program, Walter Reed Army Institute of Research, U.S. OA02.06LB. Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens Daniel Stieh, Janssen Vaccines & Prevention BV, Netherlands Oral Abstract Session 3 - Structure and Maturation of bnabs (Tuesday, 22 October ) OA Identification of Near Pan-neutralizing Antibodies Against HIV-1 by Deconvolution of Plasma Humoral Responses Mohammad Sajadi, Institute of Human Virology, University of Maryland, U.S. 1

2 Oral Abstract Session 7 - Understanding Protection Against HIV From the T Cell Perspective (Tuesday, 22 October ) OA Structure-based Network Analysis of HIV-1 Defines Protective CD8+ T Cell Epitopes Across Diverse HLA: Implications for Global Immunogen Design Gaurav Gaiha, Ragon Institute of MGH, MIT & Harvard, U.S. Oral Abstract Session 11 Novel Vaccine Strategies (Wednesday, 24 October ) OA Fusion Peptide-directed Antibodies Elicited in Immunized Rhesus Macaques Neutralized 59% of 208 Wildtype HIV-1 Strains Rui Kong, Vaccine Research Center, NIAID, National Institutes of Health, U.S. # # # 2

3 PRESS CONFERENCES HIV RESEARCH FOR PREVENTION (HIVR4P 2018) Media Center: Pottsdam/Baden Baden rooms, Madrid Marriott Auditorium Hotel Embargoes on oral abstract studies lift at the conclusion of the study s presentation in either an HIVR4P press conference or in an official conference session, whichever is earlier. Embargoes on all poster presentations lift on Tuesday, 23 October at CEST or at the conclusion of presentation of the study in an HIVR4P press conference, whichever is earlier. Embargoes apply to traditional and social media. Press conferences may be viewed live at or archived at Tuesday, 23 October (12:00 1:00 pm) CEST Pre-exposure prophylaxis (PrEP) Update Panel 1 Moderator: Mike Chirenje, University of Zimbabwe, Zimbabwe Oral Abstract Session 4 - Entry Into the PrEP Continuum (Tuesday, 22 October ) OA Tracking Global Oral PrEP Provision: The Who, What, Where of Oral PrEP Laura Fitch, AVAC, U.S. Oral Abstract Session 15 - New ARVs for Prevention (Wednesday, 24 October ) OA15.06LB. Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final Results Raphael Landovitz, UCLA Center for Clinical AIDS Research & Education, U.S. Oral Abstract Session 23 - Great Expectations: The Impact of PrEP (Thursday, 25 October ) OA HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure Prophylaxis (PrEP): Worldwide Experience From 46 Studies Jared Baeten, University of Washington, U.S. OA Decreased HIV Incidence among PrEP Users Compared to Non-Users in a Boston Community Health Center, Kenneth Mayer, Fenway Health/Harvard Medical School, U.S. 3

4 Pre-exposure prophylaxis (PrEP) Update Panel 2 Moderator: Susan Buchbinder, San Francisco Department of Public Health, U.S. Oral Abstract Session 19: Stay With Me: Retention on PrEP (Thursday, 25 October ) OA PrEP Uptake and Retention Among Men and Women Receiving PrEP Integrated in Public Health HIV Care Clinic Settings Kenneth Mugwanya, University of Washington, U.S. Oral Abstract Session 23 - Great Expectations: The Impact of PrEP (Thursday, 25 October ) OA Mathematical Modeling to Evaluate the Impact and Cost-effectiveness of Oral Pre-exposure Prophylaxis for HIV Prevention in Uganda Katharine Kripke, Avenir Health, Project SOAR, U.S. OA Transgender Women on Estrogen Have Significantly Lower Tenofovir/Emtricitabine Concentrations During Directly Observed Dosing When Compared to Cis Men Craig Hendrix, Johns Hopkins University School of Medicine, U.S. Poster Session 2 (Wednesday, 24 October ) P07.22LB. No Association Found Between Prenatal PrEP Use and Adverse Infant Outcomes: Results from a Large PrEP Implementation Program in Kenya Julia Dettinger, University of Washington, U.S. Media Roundtable: Tuesday, 23 October (2:30 3:15 pm) Three past presidents of the International AIDS Society reflect on their 2015 Lancet call for a global access to PrEP, discuss where we are now and look to the future of HIV prevention. With: Linda-Gail Bekker, Desmond Tutu HIV Centre, S. Africa Chris Beyrer, Johns Hopkins University, U.S. Anton Pozniak, Chelsea and Westminster Hospital, U.K. # # # 4

5 PRESS CONFERENCES HIV RESEARCH FOR PREVENTION (HIVR4P 2018) Media Center: Pottsdam/Baden Baden rooms, Madrid Marriott Auditorium Hotel Embargoes on oral abstract studies lift at the conclusion of the study s presentation in either an HIVR4P press conference or in an official conference session, whichever is earlier. Embargoes on all poster presentations lift on Tuesday, 23 October at CEST or at the conclusion of presentation of the study in an HIVR4P press conference, whichever is earlier. Embargoes apply to traditional and social media. Press conferences may be viewed live at or archived at Wednesday, 24 October (12:00 1:00 pm) CEST HIV Prevention for Women and Girls Moderator: Mike Chirenje, University of Zimbabwe, Zimbabwe Oral Abstract Session 23 - Great Expectations: The Impact of PrEP (Thursday, 25 October ) OA Sensitive Next-generation Sequencing of HIV-1 from Seroconverters in the MTN-020/ASPIRE Dapivirine Vaginal Ring Study Urvi Parikh, University of Pittsburgh, U.S. Oral Abstract Session 19 - Stay With Me: Retention on PrEP (Thursday, 25 October ) OA Early Persistence of HIV Pre-exposure Prophylaxis (PrEP) in African Adolescent Girls and Young Women (AGYW) from Kenya and South Africa Elzette Rousseau-Jemwa, Desmond Tutu HIV Foundation, South Africa Oral Abstract Session 10 - Key to the Response: Populations, Partners and Prevention (Wednesday, 24 October ) OA Male Partners of Adolescent Girls and Young Women (AGYW) in Durban, South Africa: How High is Their HIV Risk and What Groups are Most at Risk? Ann Gottert, Population Council, U.S. Poster Session 2 (Wednesday, 24 October ) P14.58LB. Results from PEPFAR s DREAMS Partnership: Implications for Prevention Programming for Adolescent Girls and Young Women Angeli Achrekar, Office of the U.S. Global AIDS Coordinator and Health Diplomacy, U.S. 5

6 HIV Prevention for Key Populations Moderator: Wafaa El-Sadr, ICAP at Columbia University, New York, NY, US Oral Abstract Session 10 - Key to the Response: Populations, Partners and Prevention (Wednesday, 24 October ) OA10.04LB. HIV Incidence among Men Who Save Sex with Men and Transgender Women in Sub- Saharan Africa: Findings from the Multi-country HPTN 075 Cohort Study Theo Sandfort, New York State Psychiatric Institute, U.S. OA Young Transwomen in Brazil Have High HIV Risk and Low Prevention Use Erin Wilson, San Francisco Department of Public Health, U.S. Oral Abstract Session 19 - Stay With Me: Retention on PrEP (Thursday, 25 October ) OA Early Antiretroviral Therapy and Daily Pre-exposure Prophylaxis for HIV Prevention among Female Sex Workers in Cotonou, Benin: A Demonstration Study Michel Alary, CHU de Québec - Université Laval, Canada Oral Abstract Session 10 - Key to the Response: Populations, Partners and Prevention (Wednesday, 24 October ) OA An Integrated Intervention to Increase ART and MAT Reduces Mortality among PWID: Results from the HPTN 074 Randomized Trial Kostyantyn Dumchev, Ukrainian Institute on Public Health Policy, Ukraine # # # 6

7 PRESS CONFERENCES HIV RESEARCH FOR PREVENTION (HIVR4P 2018) Media Center: Pottsdam/Baden Baden rooms, Madrid Marriott Auditorium Hotel Embargoes on oral abstract studies lift at the conclusion of the study s presentation in either an HIVR4P press conference or in an official conference session, whichever is earlier. Embargoes on all poster presentations lift on Tuesday, 23 October at CEST or at the conclusion of presentation of the study in an HIVR4P press conference, whichever is earlier. Embargoes apply to traditional and social media. Press conferences may be viewed live at or archived at Thursday, 25 October (12:00 1:00 pm) CEST HIV Prevention Policy and Funding Moderator: Mitchell Warren, AVAC, U.S. Poster Session 2 (Wednesday, 24 October ) P23.08LB. HIV Prevention Research & Development Funding Trends : Investing to End the Epidemic as a Public Health Threat Fatima Riaz, AVAC, U.S. Poster Session 1 (Tuesday, 23 October ) P23.07LB. Tracking the Impact of the Expanded Mexico City Policy on PEPFAR Implementing Partners Jennifer Sherwood, amfar, U.S New Prevention Tools and Approaches Moderator: Sharon Hillier, University of Pittsburgh, U.S. Oral Abstract Session 12 - Contraception and HIV Risk: Still Between a Rock and a Hard Place (Wednesday, 24 October ) OA12.02LB. Safety and Pharmacokinetics of Dapivirine and Levonorgestrel Vaginal Rings for Multipurpose Prevention of HIV and Pregnancy Sharon Achilles, University of Pittsburgh, U.S. 7

8 Oral Abstract Session 15 - New ARVs for Prevention (Wednesday, 24 October ) OA Dose-ranging Pharmacokinetic Assessment of Vaginally Administered EVG/TAF Inserts in Macaques for PrEP Charles Dobard, Centers for Disease Control and Prevention, U.S. Poster Discussion Session 9 - Long-acting Prevention Agents in Experimental Models (Wednesday, 24 October ) PD A Subcutaneous Biodegradable Implant for Sustained Delivery of Tenofovir Alafenamide (TAF) for HIV Pre-exposure Prophylaxis (PrEP) Leah Johnson, RTI International, U.S. Oral Abstract Session 20 - Into the Future With Delivery Technologies (Thursday, 25 October ) OA Tenofovir Douche for PrEP: On-demand, Behaviorally-congruent Douche Rapidly Achieves Colon Tissue Concentration Targets (DREAM 01 Study) Ethel Weld, Johns Hopkins University School of Medicine, U.S. # # # 8